PL2959894T3 - Modulatory receptora s1p do leczenia stwardnienia rozsianego - Google Patents

Modulatory receptora s1p do leczenia stwardnienia rozsianego

Info

Publication number
PL2959894T3
PL2959894T3 PL15177166.4T PL15177166T PL2959894T3 PL 2959894 T3 PL2959894 T3 PL 2959894T3 PL 15177166 T PL15177166 T PL 15177166T PL 2959894 T3 PL2959894 T3 PL 2959894T3
Authority
PL
Poland
Prior art keywords
multiple sclerosis
receptor modulators
treating multiple
treating
modulators
Prior art date
Application number
PL15177166.4T
Other languages
English (en)
Other versions
PL15177166T1 (pl
Inventor
Peter C. Hiestand
Christian Schnell
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36888144&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2959894(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL15177166T1 publication Critical patent/PL15177166T1/pl
Publication of PL2959894T3 publication Critical patent/PL2959894T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL15177166.4T 2006-06-27 2007-06-25 Modulatory receptora s1p do leczenia stwardnienia rozsianego PL2959894T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0612721.1A GB0612721D0 (en) 2006-06-27 2006-06-27 Organic compounds

Publications (2)

Publication Number Publication Date
PL15177166T1 PL15177166T1 (pl) 2022-03-07
PL2959894T3 true PL2959894T3 (pl) 2022-11-14

Family

ID=36888144

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15177166.4T PL2959894T3 (pl) 2006-06-27 2007-06-25 Modulatory receptora s1p do leczenia stwardnienia rozsianego

Country Status (20)

Country Link
US (3) US20100168078A1 (pl)
EP (4) EP2037906A1 (pl)
JP (8) JP2009541386A (pl)
KR (6) KR20150122812A (pl)
CN (2) CN101478961B (pl)
AU (7) AU2007264031C1 (pl)
BR (1) BRPI0713985A2 (pl)
CA (1) CA2653569C (pl)
DE (1) DE15177166T1 (pl)
DK (1) DK2959894T3 (pl)
ES (1) ES2887042T3 (pl)
GB (1) GB0612721D0 (pl)
HU (1) HUE059922T4 (pl)
LT (1) LT2959894T (pl)
MX (3) MX2008016133A (pl)
PL (1) PL2959894T3 (pl)
PT (1) PT2959894T (pl)
RU (1) RU2617502C2 (pl)
SI (1) SI2959894T1 (pl)
WO (1) WO2008000419A1 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP2142184B1 (en) * 2007-05-04 2018-10-24 Novartis AG Use of s1p receptor modulator
WO2009155475A1 (en) * 2008-06-20 2009-12-23 Novartis Ag Paediatric compositions for treating1 multiple sclerosis
CA2733508A1 (en) * 2008-08-18 2010-02-25 David Leppert Compounds for the treatment of peripheral neuropathies
EP2177521A1 (en) 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
RU2011129229A (ru) * 2008-12-18 2013-01-27 Новартис Аг Новые соли
AU2009327405A1 (en) * 2008-12-18 2011-06-30 Novartis Ag New polymorphic form of 1- (4- { l- [ (E) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
HRP20131106T1 (hr) * 2008-12-18 2013-12-20 Novartis Ag Hemifumaratna sol od 1-[4-[1-(4-cikloheksil-3-trifluorometil-benziloksiimino)-etil]-2-etil-benzil]-azetidin-3-karboksilne kiseline
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
JP5939158B2 (ja) * 2009-11-24 2016-06-22 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 治療的有用性を有する受容体調節物質としての新規化合物
EP2343287A1 (en) 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
EP2366702A1 (en) 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
SG191286A1 (en) 2011-01-07 2013-07-31 Novartis Ag Immunosuppressant formulations
CN102120720B (zh) * 2011-01-25 2013-05-22 上海华升生物科技有限公司 盐酸芬戈莫德的合成新方法
CA2852142A1 (en) * 2011-10-21 2013-04-25 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
CN104170419B (zh) * 2012-03-23 2018-11-02 日本电气株式会社 订户服务器、监视服务器、移动终端、与之相关的方法和计算机可读介质
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
WO2015053879A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
EP3054933A4 (en) * 2013-10-11 2017-03-15 Teikoku Pharma USA, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
EP3400211A1 (en) 2016-01-04 2018-11-14 Auspex Pharmaceuticals, Inc. Azetidine modulators of the sphingosine 1-phosphate receptor
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
CA3156298A1 (en) 2019-10-31 2021-05-06 Laetitia POUZOL Combination of a cxcr7 antagonist with an s1p1 receptor modulator
US20250177115A1 (en) * 2021-08-20 2025-06-05 The Brain Protection Company PTY LTD Combinatorial therapies including implantable damping devices and therapeutic agents for treating a condition and associated systems and methods of use
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB612721A (en) 1946-02-11 1948-11-17 Richard William Bailey Improvements in combustion product power plant
KR0155015B1 (ko) 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
KR100335584B1 (ko) 1992-10-28 2002-11-29 제넨테크, 인코포레이티드 혈관내피세포성장인자에대한길항제
DE69524962T4 (de) 1994-08-22 2003-08-28 Mitsubishi Pharma Corp., Osaka Benzolderivate und deren medizinische verwendung
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
ES2240868T3 (es) 1997-04-04 2005-10-16 Mitsubishi Pharma Corporation Compuesto de 2-aminopropano -1,3-diol, su uso farmaceutico e intermedios en su sintesis.
ES2342240T3 (es) 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
EP1579871A1 (en) 1998-12-22 2005-09-28 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
ATE329596T1 (de) 1999-03-30 2006-07-15 Novartis Pharma Gmbh Phthalazinderivate zur behandlung von entzündlicher erkrankungen
AR025068A1 (es) 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
WO2001058899A1 (en) 2000-02-09 2001-08-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
DE10033541C2 (de) 2000-07-11 2003-05-15 Litef Gmbh Lichtleitfaserspule für ein faseroptisches Sagnac-Interferometer und Verfahren zu ihrer Herstellung
CZ200350A3 (cs) 2000-07-13 2003-05-14 Sankyo Company Limited Aminoalkoholové deriváty
WO2002018395A1 (en) 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
RU2199339C2 (ru) 2001-02-23 2003-02-27 Общество с ограниченной ответственностью "Биотех" Способ лечения рассеянного склероза
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
DE60329073D1 (de) 2002-01-18 2009-10-15 Merck & Co Inc Edg-rezeptoragonisten
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
JP5227492B2 (ja) * 2002-05-16 2013-07-03 ノバルティス アーゲー 癌におけるｅｄｇレセプター結合剤の使用
WO2003099192A2 (en) 2002-05-27 2003-12-04 Novartis Ag Bis-aromatic alkanols
MXPA05003254A (es) 2002-09-24 2005-06-08 Novartis Ag Agonistas del receptor de esfingosina-1-fosfato en el tratamiento de trastornos de desmielinacion.
KR20040048231A (ko) 2002-12-02 2004-06-07 주식회사 두산 신생혈관생성 억제제 및 그를 포함한 암 치료용 키트
FR2848495B1 (fr) * 2002-12-12 2006-11-17 Sidel Sa Four pour chauffer au defile des ebauches de recipients en materiau thermoplastique
CA2707750A1 (en) 2003-04-08 2004-10-21 Novartis Ag Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
CN102174042B (zh) * 2003-05-19 2013-09-18 Irm有限责任公司 免疫抑制剂化合物和组合物
EP1628967B1 (en) 2003-05-19 2014-04-09 Irm Llc Immunosuppressant compounds and compositions
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
EP2583685A1 (en) * 2004-06-10 2013-04-24 Regeneron Pharmaceuticals, Inc. Method of administering and using VEGF inhibitors for the treatment of human cancer
EP2377555A3 (en) * 2004-11-18 2011-11-23 Imclone LLC Antibodies against vascular endothelial growth factor receptor-1
EP2384749A1 (en) * 2004-11-29 2011-11-09 Novartis AG Dosage regimen of an S1P receptor agonist
NZ555286A (en) * 2004-12-17 2010-04-30 Genentech Inc Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
RU2278687C1 (ru) 2005-06-16 2006-06-27 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" (ГОУ ВПО БГМУ РОСЗДРАВА РОССИИ) Способ лечения ремиттирующего рассеянного склероза
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP2323679A4 (en) 2008-07-25 2012-08-22 Univ Colorado CLIP INHIBITORS AND METHODS FOR MODULATING IMMUNE FUNCTION
GB2527550B (en) 2014-06-25 2016-09-21 Cook Medical Technologies Llc Implantable medical device with lumen constriction

Also Published As

Publication number Publication date
AU2018202210A1 (en) 2018-04-26
CN101478961A (zh) 2009-07-08
US20110237682A1 (en) 2011-09-29
US9187405B2 (en) 2015-11-17
AU2019219818A1 (en) 2019-09-12
JP2019167352A (ja) 2019-10-03
KR20140069178A (ko) 2014-06-09
JP2018109018A (ja) 2018-07-12
PL15177166T1 (pl) 2022-03-07
MX2019012750A (es) 2020-02-03
SI2959894T1 (sl) 2022-11-30
EP2037906A1 (en) 2009-03-25
RU2569732C2 (ru) 2015-11-27
JP2021035955A (ja) 2021-03-04
JP7258832B2 (ja) 2023-04-17
CN101478961B (zh) 2013-11-27
RU2013131176A (ru) 2015-01-20
CA2653569A1 (en) 2008-01-03
JP2013166761A (ja) 2013-08-29
HK1214758A1 (en) 2016-08-05
KR20210010956A (ko) 2021-01-28
AU2013200356A1 (en) 2013-02-14
EP2698154A1 (en) 2014-02-19
US20140228446A1 (en) 2014-08-14
ES2887042T1 (es) 2021-12-21
JP2025016462A (ja) 2025-02-04
DK2959894T3 (da) 2022-10-17
MX2022008950A (es) 2022-08-11
DK2959894T1 (da) 2021-12-20
KR20090024281A (ko) 2009-03-06
AU2013200356B2 (en) 2016-09-29
RU2009102278A (ru) 2010-08-10
KR20150122812A (ko) 2015-11-02
HUE15177166T1 (hu) 2022-05-28
ES2887042T3 (es) 2022-11-14
AU2007264031B2 (en) 2011-01-27
AU2007264031A1 (en) 2008-01-03
JP2009541386A (ja) 2009-11-26
AU2011201844B2 (en) 2012-10-25
DE15177166T1 (de) 2022-01-27
MX2008016133A (es) 2009-01-15
BRPI0713985A2 (pt) 2012-11-20
HUE059922T2 (hu) 2023-01-28
EP2959894B1 (en) 2022-10-12
RU2617502C2 (ru) 2017-04-25
US20100168078A1 (en) 2010-07-01
KR20190030776A (ko) 2019-03-22
AU2011201844A1 (en) 2011-05-19
AU2016266058A1 (en) 2016-12-22
KR20170138583A (ko) 2017-12-15
US8741963B2 (en) 2014-06-03
AU2007264031C1 (en) 2016-12-15
AU2021202395A1 (en) 2021-05-20
HUE059922T4 (hu) 2024-05-28
JP6931019B2 (ja) 2021-09-01
CN103550195A (zh) 2014-02-05
PT2959894T (pt) 2022-10-18
GB0612721D0 (en) 2006-08-09
EP2959894A1 (en) 2015-12-30
JP2023098949A (ja) 2023-07-11
EP3797765A1 (en) 2021-03-31
LT2959894T (lt) 2022-11-10
JP2016185957A (ja) 2016-10-27
CA2653569C (en) 2016-06-21
WO2008000419A1 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
PT2959894T (pt) Modulador de um receptor de s1p para o tratamento de esclerose múltipla
PL3028716T3 (pl) Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów
EP2079414A4 (en) SYSTEM FOR CHEMOHYPER THERMAL TREATMENT
PT2465492E (pt) Composições que compreendem moduladores de receptores de esfingosina-1-fosfato (s1p)
IL193639A0 (en) Collagenase for treating cellulite
EP2344446A4 (en) S1P RECEPTOR MODULATORS
IL197818A0 (en) Multiple sclerosis therapy
PL2487231T3 (pl) Środek do obróbki twardych powierzchni
IL198990A0 (en) Cb1 receptor modulators
LT2205720T (lt) Kompozicijos išsėtinės sklerozės gydymui
IL198352A0 (en) Modulators of neuronal regeneration
GB0701992D0 (en) Grehlin Receptor Modulators
ZA200904053B (en) Phosphonate compounds
IL204786A0 (en) Benzyl - cycloalkyl sphingosing 1 - phosphate receptor modulators
IL206192A0 (en) Modulators of neuronal regeneration
ZA200807221B (en) Collagenase for treating cellulite
ZA200901672B (en) Compounds for treating proliferative disorders
PL2043792T3 (pl) System do obróbki ciągłej
ZA200806237B (en) Cannibinoid receptor modulators
GB0722340D0 (en) Sphingosine-1-phosphate (S1P) receptor compounds
ZA200904663B (en) CB1 receptor modulators
GB0614058D0 (en) Treatment for multiple sclerosis
ZA200902586B (en) Modulators of neuronal regeneration
AU2007906261A0 (en) Therapy for multiple sclerosis
GB0607351D0 (en) Apparatus for breathalysing